CD38 and Miyoshi myopathy: The development of immunotherapies in the treatment of MM has emerged with the use of monoclonal antibodies anti-CD38 (daratumumab (DARA) and Isatuximab) and the development of Anti-BCMA CAR-T cells and bispecific antibodies.